Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone marrow transplant

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    432 result(s) found for: Bone marrow transplant. Displaying page 3 of 22.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-011818-21 Sponsor Protocol Number: UCL/09/0128 Start Date*: 2010-06-28
    Sponsor Name:University College London [...]
    1. University College London
    2.
    Full Title: Transplantation of umbilical cord blood from unrelated donors in patients with haematological diseases using a myeloablative conditioning regimen
    Medical condition: Haematological disorders
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004851 10018847 Haematological disorders HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002150-39 Sponsor Protocol Number: CCSJ148X2201 Start Date*: 2015-03-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, placebo controlled, study to evaluate the efficacy and safety of CSJ148 compared to placebo to prevent human cytomegalovirus (HCMV) replication in stem cel...
    Medical condition: human cytomegalovirus (HCMV) in stem cell transplant patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10009703 CMV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000195-98 Sponsor Protocol Number: HO134 Start Date*: 2017-08-18
    Sponsor Name:HOVON Foundation
    Full Title: A phase II trial in patients with myelofibrosis (primary, post-ET or post PV-MF) treated with the selective JAK2 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell tran...
    Medical condition: Primary myelofibrosis Polycythemia vera Essential thrombocytosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074689 Post polycythemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002544-32 Sponsor Protocol Number: UCL/15/0515 Start Date*: 2018-03-01
    Sponsor Name:University College London
    Full Title: A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first ...
    Medical condition: Relapsed/refractory Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020266 Hodgkin's disease recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020267 Hodgkin's disease refractory PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-001227-39 Sponsor Protocol Number: 779322 Start Date*: 2019-12-11
    Sponsor Name:University of Bergen, Faculty of Medicin, Department of Clinical Dentistry
    Full Title: A randomized controlled clinical trial to assess the efficacy of a combination of autologous mesenchymal stem cells and biomaterial in jaw bone regeneration prior to dental implant placement in com...
    Medical condition: Patients in need of dental implant(s) in the upper and lower jaws with presence of bone defects with loss in vertical height and < than 4 mm in lateral width
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10005958 Bone disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NO (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004101-26 Sponsor Protocol Number: TJB0601P1 Start Date*: 2006-12-13
    Sponsor Name:CHU Sart-Tilman
    Full Title: Mesenchymal stem cell infusion as prevention for graft rejection and graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning: a pilot study
    Medical condition: Patients with hematological malignancies not candidate for conventional allogeneic transplantation because of age or comorbidities.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027703 Mismatched donor bone marrow transplantation therapy LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000376-41 Sponsor Protocol Number: VORIGENIPHARM Start Date*: 2019-06-18
    Sponsor Name:Fundación de Investigación del Hospital Universitario La Paz (FIBHULP)
    Full Title: Randomized and multicenter clinical trial to evaluate the effectiveness and efficiency of a voriconazole preemptive genotyping strategy in patients with risk of aspergillosis.
    Medical condition: Invasive fungal disease in the hematologic patient.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10017528 Fungal infectious disorders HLGT
    20.0 10021881 - Infections and infestations 10040054 Sepsis, bacteraemia, viraemia and fungaemia NEC HLT
    20.0 100000004851 10029355 Neutropenias HLT
    20.0 100000004851 10076734 Chemotherapy induced neutropenia LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061187 Haematopoietic neoplasm PT
    20.0 100000004865 10059041 Allogeneic peripheral haematopoietic stem cell transplant LLT
    20.0 100000004865 10059040 Autologous peripheral haematopoietic stem cell transplant LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000534-35 Sponsor Protocol Number: CSM/CIT Start Date*: 2013-07-12
    Sponsor Name:Fundación Castellano Leonesa de Hematología y Hemoterapia (FUCALHH)
    Full Title: Phase II clinical trial in the treatment of cytopenias allogeneic post-transplant with a sequential infusion of allogeneic mesenchymal cells expanded in vitro.
    Medical condition: Allogeneic post-transplant cytopenias.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005629-65 Sponsor Protocol Number: RG_12-269 Start Date*: 2014-01-15
    Sponsor Name:University of Birmingham
    Full Title: Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding study
    Medical condition: Chronic Myeloid Leukaemia (CML) in Blast Phase
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-003212-11 Sponsor Protocol Number: ITCC-101/APAL2020D Start Date*: 2022-02-17
    Sponsor Name:Princess Máxima Center
    Full Title: A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML
    Medical condition: Children, adolescents, and young adults up to the age of 21 years with acute myeloid leukemia with a documented negative test for FLT3/ITD mutation and either: - Untreated second relapse, who are s...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001941 AML LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) AT (Trial now transitioned) SE (Trial now transitioned) IE (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001865-41 Sponsor Protocol Number: CC-5013-MM-015 Start Date*: 2007-03-27
    Sponsor Name:Celgene International Sàrl
    Full Title: A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) FR (Completed) DE (Completed) IE (Completed) CZ (Completed) AT (Completed) GB (Completed) DK (Completed) SE (Completed) IT (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-006052-14 Sponsor Protocol Number: C1071007 Start Date*: 2022-05-04
    Sponsor Name:PFIZER INC
    Full Title: A randomized, 2-arm, phase 3 study of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after undergoing auto...
    Medical condition: MULTIPLE MYELOMA
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) NL (Ongoing) AT (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-005019-15 Sponsor Protocol Number: CCTL019C2202 Start Date*: 2018-11-08
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (N...
    Medical condition: pediatric and adolescents patients with CD19positive r/r mature B-cell NHL who have relapsed after one or more prior therapies or are primary refractory.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) DE (Completed) SE (Ongoing) DK (Completed) NO (Completed) AT (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002231-18 Sponsor Protocol Number: RMHCAN1104 Start Date*: 2015-12-01
    Sponsor Name:University Southampton Hospital NHS Foundation Trust
    Full Title: A Phase I/IIa Study of Targeted Radiotherapy alone for Stem Cell Transplant Conditioning in Systemic AL Amyloidosis
    Medical condition: AL-Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10024460 Light chain disease myeloma associated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-001326-25 Sponsor Protocol Number: MK-8228-030 Start Date*: 2019-05-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase 2b open-label, single-arm study to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in pediatric participants from birth to less than 18 years of age at risk of de...
    Medical condition: Cytomegalovirus (CMV) infection in pediatric allogeneic HSCT recipients
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) Outside EU/EEA FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-003468-19 Sponsor Protocol Number: ADVL0912 Start Date*: 2020-08-14
    Sponsor Name:Children’s Oncology Group
    Full Title: ADVL0912: A PHASE 1/2 STUDY OF PF02341066, AN ORAL SMALL MOLECULE INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE (ALK) AND C-MET, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID TUMORS AND ANAPLASTIC LARGE CEL...
    Medical condition: malignant solid tumors including Inflammatory myofibroblastic tumor (IMT) and anaplastic large-cell lymphoma (ALCL)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-014980-38 Sponsor Protocol Number: TJB0909P1 Start Date*: 2010-07-06
    Sponsor Name:CHU de Liège
    Full Title: Co-transplantation of mesenchymal stem cells and HLA-mismatched allogeneic hematopoietic cells after reduced-intensity conditioning: a phase II randomized double-blind study.
    Medical condition: Hematological malignancies confirmed histologically and not rapidly progressing: - AML in Complete Remission; - ALL in Complete Remission; - CML unresponsive/intolerant to Imatinib but not in b...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10027703 Mismatched donor bone marrow transplantation therapy PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000722-26 Sponsor Protocol Number: AVM-003-HC Start Date*: 2021-01-11
    Sponsor Name:AlloVir, Inc.
    Full Title: Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Trans...
    Medical condition: Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004862 10059348 Viral hemorrhagic cystitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007612-29 Sponsor Protocol Number: UCL/09/0050 Start Date*: 2013-02-26
    Sponsor Name:University College London
    Full Title: Immunotherapy with CD19ζ chimeric antigen receptor gene-modified EBV-specific CTLs after stem cell transplant in children with high-risk acute lymphoblastic leukaemia
    Medical condition: The medical condition under investigation is childhood precursor B acute lymphoblastic leukaemia (ALL).
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011152-22 Sponsor Protocol Number: GTG003.08 Start Date*: Information not available in EudraCT
    Sponsor Name:GENETHON
    Full Title: Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome
    Medical condition: Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome. An open labelled, non-randomised, phase I/II, cohort study involving a single infusion of autolo...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 10:20:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA